Bonifacio, M., Binotto, G., Maino, E., Calistri, E., Marin, L., Scaffidi, L., . . . Tiribelli, M. (2015). Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica.
Chicago Style CitationBonifacio, Massimiliano, et al. "Imatinib-treated Chronic Myeloid Leukemia Patients With Discordant Response between Cytogenetic and Molecular Tests At 3 and 6 Month Time-points Have a Reduced Probability of Subsequent Optimal Response." Haematologica 2015.
Cita MLABonifacio, Massimiliano, et al. "Imatinib-treated Chronic Myeloid Leukemia Patients With Discordant Response between Cytogenetic and Molecular Tests At 3 and 6 Month Time-points Have a Reduced Probability of Subsequent Optimal Response." Haematologica 2015.